Company news
Eupraxia Pharmaceuticals, Inc. news in 2023
Eupraxia Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.
Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE Trial
December 12, 2023
Eupraxia Pharmaceuticals Announces Clinical and Corporate Update
December 11, 2023
Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial Results
November 14, 2023
Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of Rheumatology
November 1, 2023
Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic Esophagitis
October 11, 2023
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023
Eupraxia Pharmaceuticals Announces Change of Auditor
September 7, 2023
Eupraxia Pharmaceuticals Announces Presentation at PAINWeek 2023
September 6, 2023
Eupraxia Pharmaceuticals Announces Closing of Non-Brokered Private Placement for Gross Proceeds of C$22,287,125
August 18, 2023
Eupraxia Pharmaceuticals Reports Second Quarter 2023 Financial Results
August 11, 2023
Eupraxia Pharmaceuticals Announces a Non-Brokered Private Placement of up to C$22 Million
August 4, 2023
Eupraxia Pharmaceuticals Reports Positive Topline Data in its Phase 2b Osteoarthritis Trial with EP-104IAR
June 26, 2023
Eupraxia Pharmaceuticals Announces Filing of Preliminary Base Shelf Prospectus
June 15, 2023
Eupraxia Pharmaceuticals Receives U.S. FDA Fast Track Designation for EP-104IAR in Treatment of Osteoarthritis
June 13, 2023
Eupraxia Pharmaceuticals Doses First Patient in Phase 1b/2a Eosinophilic Esophagitis Trial
June 8, 2023
Eupraxia Pharmaceuticals Announces Last Patient Last Visit in Phase 2 Osteoarthritis Clinical Trial of EP-104IAR
May 25, 2023
Eupraxia Pharmaceuticals Announces Appointment of Dr. Mark Kowalski as Chief Medical Officer
May 18, 2023
Eupraxia Pharmaceuticals Reports First Quarter 2023 Financial Results
May 11, 2023
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial Results
March 23, 2023